Literature DB >> 8818654

Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells.

P P Liu1, C Wijmenga, A Hajra, T B Blake, C A Kelley, R S Adelstein, A Bagg, J Rector, J Cotelingam, C L Willman, F S Collins.   

Abstract

An expressed gene formed by fusion between the CBFB transcription factor gene and the smooth muscle myosin heavy chain gene MYH11 is consistently detected by reverse transcription polymerase chain reaction (RT-PCR) in patients who have acute myeloid leukemia (AML) subtype M4Eo with an inversion of chromosome 16. We have previously shown that a CBFB-MYH11 cDNA construct can produce a chimeric protein and transform NIH 3T3 cells. However, the presence of the chimeric protein in patient cells has not been demonstrated previously. Here, we show that such chimeric proteins can be identified in vivo, primarily in the nuclei of the leukemic cells, by use of antibodies against the C-terminus of the smooth muscle myosin heavy chain and the fusion junction peptide. A very high molecular weight protein/DNA complex is generated when nuclear extracts from patient cells are used in electrophoretic mobility shift assays, as seen in NIH 3T3 cells transfected with the CBFB-MYH11 cDNA. Immunofluorescence staining shows that the proteins are organized in vivo into novel structures within cell nuclei. One isoform of the transcript of the CBFB-MYH11 fusion gene, containing the MHC204 C-terminus, was the predominant from in all five cases studied.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818654     DOI: 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

1.  A 12-Mb complete coverage BAC contig map in human chromosome 16p13.1-p11.2.

Authors:  Y Cao; H L Kang; X Xu; M Wang; S H Dho; J R Huh; B J Lee; F Kalush; D Bocskai; Y Ding; J G Tesmer; J Lee; E Moon; V Jurecic; A Baldini; H U Weier; N A Doggett; M I Simon; M D Adams; U J Kim
Journal:  Genome Res       Date:  1999-08       Impact factor: 9.043

2.  Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1.

Authors:  Yasuhiko Kamikubo; Ling Zhao; Mark Wunderlich; Takeshi Corpora; R Katherine Hyde; Thomas A Paul; Mondira Kundu; Lisa Garrett; Sheila Compton; Gang Huang; Linda Wolff; Yoshiaki Ito; John Bushweller; James C Mulloy; P Paul Liu
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

3.  An atlas of transposable element-derived alternative splicing in cancer.

Authors:  Evan A Clayton; Lavanya Rishishwar; Tzu-Chuan Huang; Saurabh Gulati; Dongjo Ban; John F McDonald; I King Jordan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-02-10       Impact factor: 6.237

4.  Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.

Authors:  Tanawan Kummalue; Jianrong Lou; Alan D Friedman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

Review 5.  Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.

Authors:  Ya-Huei Kuo; Jing Qi; Guerry J Cook
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

6.  The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor.

Authors:  B Lutterbach; Y Hou; K L Durst; S W Hiebert
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

7.  inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

Authors:  Sebastian Schwind; Colin G Edwards; Deedra Nicolet; Krzysztof Mrózek; Kati Maharry; Yue-Zhong Wu; Peter Paschka; Ann-Kathrin Eisfeld; Pia Hoellerbauer; Heiko Becker; Klaus H Metzeler; John Curfman; Jessica Kohlschmidt; Thomas W Prior; Jonathan E Kolitz; William Blum; Mark J Pettenati; Paola Dal Cin; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Stefano Volinia; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

8.  HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.

Authors:  Jing Qi; Sandeep Singh; Wei-Kai Hua; Qi Cai; Shi-Wei Chao; Ling Li; Hongjun Liu; Yinwei Ho; Tinisha McDonald; Allen Lin; Guido Marcucci; Ravi Bhatia; Wei-Jan Huang; Chung-I Chang; Ya-Huei Kuo
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

9.  Modelling acute myeloid leukaemia in a continuum of differentiation states.

Authors:  H Cho; K Ayers; L DePills; Y-H Kuo; J Park; A Radunskaya; R Rockne
Journal:  Lett Biomath       Date:  2018-06-18

10.  CBFβ-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia initiation in mice.

Authors:  Qi Cai; Robin Jeannet; Wei-Kai Hua; Guerry J Cook; Bin Zhang; Jing Qi; Hongjun Liu; Ling Li; Ching-Cheng Chen; Guido Marcucci; Ya-Huei Kuo
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.